- Home
- HRTX vs SUIG Comparison
HRTX vs SUIG Comparison
Compare HRTX & SUIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRTX | SUIG |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | 128 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2M | 71.8M |
| IPO Year | 2007 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HRTX | SUIG |
|---|---|---|
| Price | $0.31 | $1.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.50 | ★ $5.75 |
| AVG Volume (30 Days) | ★ 2.0M | 653.6K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,904,000.00 | $3,898,631.00 |
| Revenue This Year | $15.28 | $49.95 |
| Revenue Next Year | $20.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.36 | ★ 18.10 |
| 52 Week Low | $0.30 | $0.79 |
| 52 Week High | $1.58 | $4.71 |
Technical Indicators
Market Signals| Indicator | HRTX | SUIG |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 49.72 |
| Support Level | $0.30 | $0.84 |
| Resistance Level | $0.34 | $1.54 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 41.64 | 27.03 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About SUIG Sui Group Holdings Limited
Sui Group Holdings Ltd operates a treasury management business. It has established a publicly traded SUI treasury, backed by an exclusive relationship with the Sui Foundation, an independent organization dedicated to the advancement and adoption of the Sui network. The company executes its business by acquiring SUI tokens through open-market purchases, institutional-grade deal flow typically reserved for cryptocurrency funds, and a negotiated purchase agreement with the Sui Foundation. It is focused on capitalizing on technology trends and ecosystem growth relating to SUI, while providing liquid and institutional-grade access to blockchains. The company has one reportable segment, which is a digital asset platform focused on maximizing SUI per share value and advancing the Sui ecosystem.